Search
Search Results
-
Pulsed electric field induces exocytosis and overexpression of MAGE antigens in melanoma
Nanosecond pulsed electric field (nsPEF) has emerged as a promising approach for inducing cell death in melanoma, either as a standalone treatment or...
-
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
BackgroundMEK inhibitors (MEKi) were shown to be clinically insufficiently effective in patients suffering from BRAF wild-type (BRAF WT) melanoma,...
-
Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development
PurposeNuclear accumulation of YAP/TAZ promotes tumorigenesis in several cancers, including melanoma. Although the mechanisms underlying the nuclear...
-
Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma
BackgroundMelanoma is the most lethal skin cancer characterized by its high metastatic potential. In the past decade, targeted and immunotherapy have...
-
Long non-coding RNA CCHE1 modulates LDHA-mediated glycolysis and confers chemoresistance to melanoma cells
Melanoma is considered as the most common metastatic skin cancer with increasing incidence and high mortality globally. The vital roles of long...
-
Breaking NGF–TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection
Melanoma cells, deriving from neuroectodermal melanocytes, may exploit the nervous system’s immune privilege for growth. Here we show that nerve...
-
TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism
Melanomas are characterised by accelerated cell proliferation and metabolic reprogramming resulting from the contemporary dysregulation of the MAPK...
-
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
B cells are known to contribute to the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not...
-
Melanoma stimulates the proteolytic activity of HaCaT keratinocytes
BackgroundKeratinocytes constitute a major part of the melanoma microenvironment, considering their protective role towards melanocytes in...
-
Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy
Cellular senescence is a therapy endpoint in melanoma, and the senescence-associated secretory phenotype (SASP) can affect tumor growth and...
-
Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness
BackgroundMucosal Melanomas (MM) are highly aggressive neoplasms arising from mucosal melanocytes. Current treatments offer a limited survival...
-
Immunotherapy in Melanoma and Merkel Cell Cancer
Malignant melanoma is one of the most aggressive and lethal forms of skin cancer, with incidence rates continuing to rise due to increased sun...
-
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells
BackgroundThe C-terminal-binding protein 1/brefeldin A ADP-ribosylation substrate (CtBP1/BARS) acts both as an oncogenic transcriptional co-repressor...
-
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Melanoma is the deadliest form of skin cancer and considered intrinsically resistant to chemotherapy. Nearly all melanomas harbor mutations that...
-
Delineating the early dissemination mechanisms of acral melanoma by integrating single-cell and spatial transcriptomic analyses
Acral melanoma (AM) is a rare subtype of melanoma characterized by a high incidence of lymph node (LN) metastasis, a critical factor in tumor...
-
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and...
-
Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells
cGAS/STING axis is the major executor of cytosolic dsDNA sensing that leads to the production of type I interferon (IFNI) not only upon bacterial...
-
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial
The critical roles of CD4 + T cells have been understudied for cancer vaccines. Here we report long-term clinical outcomes of a randomized multicenter...
-
Tumorous IRE1α facilitates CD8+T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma
BackgroundTumor cells frequently suffer from endoplasmic reticulum (ER) stress. Previous studies have extensively elucidated the role of tumorous...
-
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
Despite advancements in treating metastatic melanoma, many patients exhibit resistance to targeted therapies. Our study focuses on ATP1A1, a sodium...
